Bikash Chingshubam
Department of Dermatology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India.
Int J Trichology. 2025 Jan-Feb;17(1):13-19. doi: 10.4103/ijt.ijt_8_23. Epub 2025 Jun 23.
Topical hair growth supplements in the form of hair growth serums, oils, and shampoos have flooded the cosmeceutical market. The gullible masses are targeted with sponsored marketing gimmicks through social media platforms. This review article brings to light the most hyped active ingredients or peptides in these products along with their clinical evidence available in the literature. The topical actives include Redensyl, Procapil, Capixyl, Baicapil, AnaGain, onion juice, coffee extract, saw palmetto extract, pumpkin seed oil (PSO), and rosemary oil. PubMed, Google Scholar, and Google databases were searched with the keywords: topical, hair growth, hair loss, and the respective active agents. Twenty-four relevant articles and technical files were extracted and reviewed. They have been studied mostly as combined formulations with other agents in randomized controlled trials or prospective cohort studies and have shown promising results. However, most of the studies have limited sample size, lack of comparison with standard therapies, nonuniformity between study groups, nondisclosure of the type of alopecia treated, and conflicts of interest. These topicals with their less significant side effect profile may find their use as an add-on therapy or as an alternative in patients not tolerating standard therapies. In this fast-growing commercialized world, it is imperative that we remain vigilant and understand the pros and cons of these products and ultimately guide our patients to the right track.
以生发精华液、生发油和洗发水形式存在的局部用头发生长补充剂充斥着药妆市场。易受骗的大众通过社交媒体平台成为赞助营销噱头的目标。这篇综述文章揭示了这些产品中最受炒作的活性成分或肽以及文献中可用的临床证据。局部活性成分包括Redensyl、Procapil、Capixyl、Baicapil、AnaGain、洋葱汁、咖啡提取物、锯棕榈提取物、南瓜籽油(PSO)和迷迭香油。使用关键词“局部用、头发生长、脱发”以及各自的活性剂在PubMed、谷歌学术和谷歌数据库中进行了搜索。提取并审查了24篇相关文章和技术文件。它们大多在随机对照试验或前瞻性队列研究中作为与其他药物的联合制剂进行了研究,并显示出有希望的结果。然而,大多数研究样本量有限,缺乏与标准疗法的比较,研究组之间不一致,未披露所治疗的脱发类型以及存在利益冲突。这些局部用药副作用较小,可能会被用作辅助治疗或不耐受标准疗法患者的替代疗法。在这个快速发展的商业化世界中,我们必须保持警惕,了解这些产品的利弊,并最终引导我们的患者走上正确的道路。